Kratos Research Labs

KRL10 RUO launch access: documentation-led small-order review, product docs, and gated catalog access after RUO acknowledgement. Send KRL10 review request. Research use only; not for human or veterinary use.

Category: Research Summaries

  • What Does the Published Research Say About CJC-1295 Without DAC?

    Research Context

    This synthesis isolates what the included literature shows—and does not show—about CJC-1295 without DAC. The packet contains: two human study sources (a pharmacodynamic study in healthy adults and a human biomarker study; plus a clinical trial registry entry in a disease-specific context), one netnographic review source, and three preclinical/analytical sources. Importantly, the direct human data provided (e.g., [pubmed:16352683], [pubmed:19386527]) describe a long-acting CJC-1295 GHRH analog; these should not be treated as interchangeable with a non-DAC variant.

    Key Takeaway

    Most direct human findings in this packet concern a long-acting CJC-1295 formulation, not a non-DAC variant. Evidence shows GH/IGF-1 biomarker changes and lists a disease-specific trial, but no human outcome data specific to a non-DAC variant are included.

    Direct Answer

    Published research in this packet shows that a long-acting CJC-1295 GHRH analog can prolong GH and IGF-1 secretion in healthy adults and alter serum protein profiles (biomarker-level findings) [pubmed:16352683][pubmed:19386527]. A clinical trial was registered to evaluate CJC-1295 in HIV-associated visceral obesity, but no peer-reviewed outcomes are provided here [clinicaltrials:NCT00267527]. Netnographic review literature documents non-medical use narratives [pubmed:26771670]. Analytical studies in equine matrices describe detection methods, not therapeutic effects [pubmed:30938069][pubmed:30489688]. These sources do not establish clinical outcomes for a non-DAC CJC-1295 variant.

    —

    Direct Human Evidence

    • Pharmacodynamic study (healthy adults): A long-acting CJC-1295 GHRH analog produced prolonged stimulation of GH and IGF-1 secretion. Context noted that native GHRH has short duration, motivating evaluation of longer-acting analogs [pubmed:16352683].
    • Human biomarker/mechanistic study (normal adults): Activation of the GH/IGF-1 axis by CJC-1295 (long-acting GHRH analog) was associated with changes in serum protein profiles. This is biomarker-level/mechanistic evidence and not controlled clinical outcome data [pubmed:19386527].
    • Disease-specific clinical trial registry entry: A study was registered to evaluate CJC-1295 in HIV patients with visceral obesity; the packet does not provide peer-reviewed outcomes from this trial [clinicaltrials:NCT00267527].

    Variant alignment clarification: The human studies above pertain to a long-acting CJC-1295 formulation. Given this article’s focus on “CJC-1295 without DAC,” these data should not be used as stand-in evidence for a non-DAC variant.

    —

    Review and Observational Context

    • Netnography of female use narratives: Documents online “folk pharmacology” describing interests such as muscle enhancement, fat loss, and skin appearance related to CJC-1295. This frames context but does not constitute primary human outcome evidence [pubmed:26771670].

    —

    Preclinical, Mechanistic, and Analytical Evidence

    • Analytical method development (equine plasma):
    • LC–MS/MS method to confirm CJC-1295 in equine plasma [pubmed:30938069].
    • Immuno-PCR screening for GHRH analogs in equine plasma [pubmed:30489688].

    These are analytical/anti-doping methods, not therapeutic or outcome studies.

    • Human biomarker/mechanistic example (for clarity, still human, not outcomes): Serum protein profile changes consistent with GH/IGF-1 axis activation following exposure to a long-acting GHRH analog [pubmed:19386527]. This informs mechanism/biomarkers but not clinical efficacy.

    These findings should not be presented as established human therapeutic outcomes.

    —

    What Is Not Established

    • No direct human outcome data specific to a non-DAC CJC-1295 variant are included in this packet.
    • Dosing and general safety across off-label or non-study populations are not addressed here.
    • Biomarker changes (GH/IGF-1, serum protein profiles) do not establish clinical benefit [pubmed:16352683][pubmed:19386527].
    • Extrapolation from a disease-specific registry entry (HIV-associated visceral obesity) to broader populations or indications is not supported without published outcomes [clinicaltrials:NCT00267527].
    • Analytical method papers in equine models are not evidence of therapeutic effects [pubmed:30938069][pubmed:30489688].

    —

    Conclusion

    Within this packet, human evidence centers on long-acting CJC-1295 analogs that modulate GH/IGF-1 and associated biomarkers, plus a trial registered in a specific disease context without outcomes provided. These sources do not establish clinical outcomes for a non-DAC CJC-1295 variant, and they do not support generalized wellness, aesthetic, or performance claims.

    —

    FAQ

    • Does this packet include human outcome data for a non-DAC CJC-1295 variant?
    • No. The human evidence provided pertains to a long-acting formulation; no direct human outcome data specific to a non-DAC variant are included.
    • What human findings are reported for CJC-1295 in this packet?
    • Prolonged GH and IGF-1 secretion in healthy adults and serum protein profile changes consistent with GH/IGF-1 axis activation—both biomarker-level findings, not demonstrated clinical outcomes [pubmed:16352683][pubmed:19386527].
    • Is there a disease-specific clinical trial?
    • A study in HIV-associated visceral obesity is registered, but this packet does not include peer-reviewed outcome data from that trial [clinicaltrials:NCT00267527].
    • Do the equine detection studies inform therapeutic effects in humans?
    • No. They describe analytical methods for detecting CJC-1295 or related analogs in equine plasma, not therapeutic outcomes [pubmed:30938069][pubmed:30489688].
    • Can biomarker changes be interpreted as proof of benefit?
    • No. Mechanistic/biomarker signals (e.g., GH/IGF-1 increases, serum protein shifts) do not establish clinical efficacy [pubmed:16352683][pubmed:19386527].

    —

    References

    • Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. https://pubmed.ncbi.nlm.nih.gov/16352683/ [pubmed:16352683]
    • Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. https://pubmed.ncbi.nlm.nih.gov/26771670/ [pubmed:26771670]
    • A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. https://pubmed.ncbi.nlm.nih.gov/30938069/ [pubmed:30938069]
    • An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. https://pubmed.ncbi.nlm.nih.gov/30489688/ [pubmed:30489688]
    • Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. https://pubmed.ncbi.nlm.nih.gov/19386527/ [pubmed:19386527]
    • A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. https://clinicaltrials.gov/study/NCT00267527 [clinicaltrials:NCT00267527]
    • PubChem compound record: CJC 1295. https://pubchem.ncbi.nlm.nih.gov/compound/91971820 [pubchem:91971820]
    • Google Patents search for CJC-1295. https://patents.google.com/?q=CJC-1295 [patent_search:cjc-1295]

  • What Does the Published Research Say About TB-500?

    Research Context

    • Nomenclature and heterogeneity: TB-500 is a label used for thymosin beta-4 (Tβ4)–related peptides. Analytical work has identified an N-terminal acetylated 17–23 fragment of Tβ4 in some products marketed as TB-500, particularly in doping-control contexts; product composition may vary and these findings should not be presumed universal across all products [semantic:10.1002/dta.1402]. These analytical data inform detection/regulatory discussions, not demonstrated efficacy.
    • Evidence mix in the packet: The packet includes human-context evidence in a vascular injury/restenosis setting (pathway-focused, not TB-500 administration) [pubmed:39873228], alongside a scoping review preprint [crossref:10.20944/preprints202605.1124.v1] and multiple reviews and preclinical/mechanistic sources. Reviews frame biological plausibility and translational context but do not replace primary human outcome evidence [pubmed:41490200; pubmed:17468232; pubmed:17495248; pubmed:41476424; pubmed:38994967].
    • Clarifying scope: Direct human evidence exists in the packet but is narrow and should remain tied to the specific population and endpoints studied; it does not constitute interventional efficacy data for marketed TB-500 products [pubmed:39873228; crossref:10.20944/preprints202605.1124.v1].
    • Measurement caveat: Quantifying circulating Tβ4 shows assay-related variability; biomarker claims should be made cautiously [pubmed:29502471].
    • Scope limit: Conclusions below are confined to the supplied sources. Dosing, standardized safety, long-term outcomes, and broad efficacy/generalizability are not established in this packet.

    Key Takeaway

    Published research on TB-500 centers on thymosin beta-4 biology, with narrow human-context evidence tied to vascular injury pathways and no identified interventional trials of TB-500.

    Direct Answer

    • TB-500 is best understood as a Tβ4-related product; some marketed materials have been analytically identified as an N-acetylated Tβ4 17–23 fragment, but composition can vary. Much of the literature addresses endogenous Tβ4 biology rather than specific TB-500 formulations [semantic:10.1002/dta.1402].
    • The packet contains narrow, context-specific human evidence related to a CCN5–Tβ4–CD9 axis in vascular injury/restenosis and endothelial repair; this should not be interpreted as interventional efficacy data for TB-500 and should remain anchored to the studied population and endpoints [pubmed:39873228].
    • Most cited sources are reviews or preclinical/mechanistic; they provide rationale and hypotheses but do not establish clinical utility for TB-500 [pubmed:41490200; pubmed:17468232; pubmed:17495248; pubmed:41476424; pubmed:22074294].
    • No randomized or controlled interventional human trials of TB-500 are identified in the supplied packet.

    Human Evidence (from the packet)

    • Vascular injury/restenosis context: One PubMed source implicates a CCN5–Tβ4–CD9 axis in suppressing injury-induced vascular restenosis and facilitating endothelial repair. Any conclusions should remain tied to the specific population, endpoints, and biological context described. This source does not evaluate interventional TB-500 administration and does not establish interventional efficacy for TB-500 products [pubmed:39873228].
    • Scoping review preprint: A scoping review on Tβ4 and TB-500 is included as a preprint; treat it as contextual review (not peer-reviewed primary human interventional evidence). Regardless of any summarized observations, it does not substitute for controlled human trials [crossref:10.20944/preprints202605.1124.v1].

    Practical boundary: When referencing human outcomes, do not imply that TB-500 (as marketed) was tested in randomized or controlled interventional human trials based on these sources. Keep statements narrowly aligned to the specific human context in the packet [pubmed:39873228].

    Review Context (mechanisms and translational framing)

    • Orthopaedics and sports medicine overviews discuss therapeutic peptides and mechanistic rationales for tissue repair/rehabilitation but do not provide primary clinical outcome evidence for TB-500 [pubmed:41490200; pubmed:41476424].
    • Reviews on beta-thymosins outline biology, distribution, and functional considerations relevant to Tβ4, supplying background but not proving clinical efficacy for TB-500 [pubmed:17468232; pubmed:17495248; pubmed:38994967].
    • Structural and cardioprotection-focused reviews detail Tβ4 structures and potential roles, largely in nonclinical contexts; these are hypothesis-generating, not established human outcomes [pubmed:27450728; pubmed:27450736].
    • Biomarker methods highlight variability in circulating Tβ4 assays, cautioning against strong inferences without standardized techniques [pubmed:29502471].

    How to use these reviews: as mechanistic/translational context and hypothesis generation. They do not substitute for primary, controlled human outcomes.

    Preclinical, Analytical, and Mechanistic Findings

    • Regeneration/repair biology: Nonclinical literature describes Tβ4 as involved in cellular repair and regeneration; such findings are hypothesis-generating and not equivalent to human clinical outcomes [pubmed:22074294].
    • Molecular interactions and structure: Work on Tβ4 interactions and structures informs mechanism but does not provide clinical endpoints [pubmed:12852258; pubmed:27450728].
    • Immune cell effects: Tβ4 and Tβ4-derived peptides can induce mast cell exocytosis in experimental systems; this is mechanistic, nonclinical evidence and not a demonstrated human outcome [crossref:10.1016/j.peptides.2007.01.004].
    • Cardiovascular context: A review discusses potential cardioprotective roles of Tβ4; in the provided sources this remains preclinical/mechanistic [pubmed:27450736].
    • Analytical/forensic identification: An N-acetylated 17–23 Tβ4 fragment has been identified in some products suspected of TB-500 doping; this supports nomenclature/identity clarification but not efficacy or safety claims [semantic:10.1002/dta.1402].

    Boundary condition: Preclinical and analytical findings should not be reframed as demonstrated human benefit or safety.

    Gaps and Open Questions

    • Generalized clinical efficacy for TB-500 across indications is not established; do not extrapolate beyond the specific human context identified in the packet [pubmed:39873228].
    • No randomized or controlled interventional human trials of TB-500 are identified in the packet; most sources are reviews or preclinical.
    • Dosing, standardized safety profiles, and long-term outcomes for TB-500 in humans are not defined by the supplied evidence.
    • Biomarker interpretation is limited by assay variability for circulating Tβ4 [pubmed:29502471].
    • Registry entries and patent searches are not efficacy evidence and should not be used as such [pubchem:62707662; patent_search:tb-500-tb500-thymosin-beta-4-thymosin-4].

    FAQ

    • Is there direct human evidence related to TB-500/Tβ4 in this packet?
    • The packet indicates direct human evidence exists but is narrow and pathway-focused in a vascular injury/restenosis context; it does not show interventional efficacy for marketed TB-500 products [pubmed:39873228; crossref:10.20944/preprints202605.1124.v1].
    • Are there randomized or controlled interventional human trials of TB-500 in the supplied sources?
    • No. The packet does not identify any randomized or controlled interventional trials of TB-500.
    • What exactly is TB-500 in the literature?
    • It refers to Tβ4-related peptides; analytical work has identified an N-acetylated Tβ4 17–23 fragment in some products, and composition may vary across marketed materials [semantic:10.1002/dta.1402].
    • Can circulating Tβ4 be used as a reliable biomarker here?
    • Caution is warranted; methodological variability complicates quantification and interpretation of circulating Tβ4 [pubmed:29502471].
    • Do reviews establish clinical efficacy for TB-500?
    • No. Reviews provide mechanistic and translational context but do not substitute for primary human outcome evidence [pubmed:41490200; pubmed:41476424; pubmed:17468232; pubmed:17495248; pubmed:38994967].

    References

    • Human-context study (pathway/biological context; not TB-500 administration):
    • [pubmed:39873228]
    • Reviews/translational and methods context:
    • [pubmed:41490200], [pubmed:41476424], [pubmed:17468232], [pubmed:17495248], [pubmed:38994967], [pubmed:27450728], [pubmed:27450736], [pubmed:29502471], [crossref:10.20944/preprints202605.1124.v1]
    • Preclinical/mechanistic and analytical:
    • [pubmed:22074294], [pubmed:12852258], [crossref:10.1016/j.peptides.2007.01.004], [semantic:10.1002/dta.1402]
    • Identifiers/registries (not efficacy evidence):
    • [pubchem:62707662], [patent_search:tb-500-tb500-thymosin-beta-4-thymosin-4]

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Dilute Acetic Acid as a Laboratory Reagent?

    Research Context

    The packet is heterogeneous. It includes: (a) one human clinical study in hemodialysis patients evaluating propolis (not a reagent study) [pubmed:39453192]; (b) a clinical nutrition meta-analysis on vinegar ingestion and metabolic endpoints [pubmed:28292654]; (c) domain reviews not focused on laboratory reagent performance [pubmed:30074030; pubmed:16202844; pubmed:36985356]; (d) preclinical/methods/informatics papers that do not directly assess dilute acetic acid as a peptide-focused reagent [pubmed:31472480; pubmed:38117889; pubmed:38359688]; (e) engineering/processing items involving dilute acetic acid outside peptide/proteomics scope [crossref:10.1021/acssuschemeng.1c02937.s001; crossref:10.58837/chula.the.2006.1639]; and (f) standards/monographs for acetic acid grades [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401].

    Key Takeaway

    Within this packet, no primary bench studies evaluate dilute acetic acid performance in peptide or proteomics workflows. Standards list grades; clinical, review, preclinical, methods, and engineering items are contextual only and should not be extrapolated to reagent efficacy.

    Direct Answer

    • Within this packet, there are no primary bench studies that directly evaluate dilute acetic acid as a laboratory reagent for peptide solubilization, sample preparation, LC–MS performance, or related workflow metrics [pubmed:31472480; pubmed:38117889; pubmed:38359688].
    • Standards/monographs specify acetic acid grades (e.g., glacial, dilute, ultratrace) but, within this packet, they do not validate performance for peptide/proteomics workflows [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401].
    • Human clinical literature included here (propolis in hemodialysis; vinegar ingestion meta-analysis) addresses unrelated endpoints and should not be extrapolated to laboratory reagent performance [pubmed:39453192; pubmed:28292654].

    Human Evidence (Clinical)

    • A clinical study of propolis in patients undergoing hemodialysis reports effects on gut microbiota and uremic toxin profiles [pubmed:39453192]. This is unrelated to dilute acetic acid and does not evaluate laboratory reagent performance.

    Review and Translational Context (Not Primary Evidence)

    • A systematic review/meta-analysis on vinegar ingestion and postprandial glucose/insulin responses examines dietary exposure and metabolic endpoints, not laboratory reagent performance [pubmed:28292654].
    • Additional domain reviews (e.g., polyketide synthase–NRPS interactions; cerumen removal products; phosphate-solubilizing bacteria) are tangential and should not be interpreted as evidence for dilute acetic acid as a peptide/proteomics reagent [pubmed:30074030; pubmed:16202844; pubmed:36985356].
    • Other screened literature (e.g., tryptophan metabolites and Aβ; silicate- or phosphate-solubilizing bacteria; peptide 14C-labeling) provides mechanistic or domain-specific context only, not reagent performance data [pubmed:32360535; pubmed:34225007; pubmed:36494624; pubmed:3379315].

    Preclinical, Methods, Engineering, and Standards (Context Only)

    • Methods/informatics papers in the packet do not establish dilute acetic acid usage or quantify concentration–performance relationships for peptide workflows:
    • Microwave-assisted acid hydrolysis for whole-bone proteomics/paleoproteomics is a sample-prep method paper and does not evaluate dilute acetic acid for peptide solubilization performance [pubmed:31472480].
    • Cobalt-catalyzed umpolung hydrogenation for unnatural peptide synthesis is synthetic methodology unrelated to acetic acid as a solubilizing reagent or sample-prep additive [pubmed:38117889].
    • LC–MS retention-time prediction for phosphorylated peptides is computational/informatics work and does not test dilute acetic acid as a mobile-phase additive or assess concentration–performance tradeoffs [pubmed:38359688].
    • Engineering/processing items are out of scope for peptide/proteomics reagent performance:
    • Dilute acetic acid hydrolysis for xylooligosaccharide production in biomass processing does not assess peptide workflows [crossref:10.1021/acssuschemeng.1c02937.s001].
    • Reactive distillation using dilute acetic acid to produce n-butyl acetate is a process engineering study, not a reagent performance evaluation for peptides [crossref:10.58837/chula.the.2006.1639].
    • Standards/monographs specify properties and grades (e.g., glacial vs dilute; ultratrace) but, within this packet, are not empirical demonstrations of performance in peptide or proteomics workflows [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401]. Patent listings are non-evidentiary for performance claims [patent_search:dilute-acetic-acid-peptide-solubilization-laboratory-reagent].

    What Is Not Established Within This Packet

    • Direct bench evidence validating dilute acetic acid for peptide recovery, compatibility, LC–MS performance, or other workflow metrics in proteomics or related laboratory applications is not present [pubmed:31472480; pubmed:38117889; pubmed:38359688].
    • While standards/monographs may include limited procedural notes, they do not provide protocol-level guidance or comparative performance validation for laboratory use here [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401].
    • Dosing, concentration, safety parameters, and standard-of-use protocols for dilute acetic acid in laboratory workflows are not established by the materials in this packet [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401].

    Notes for Researchers

    • If considering dilute acetic acid for a workflow, design bench-level comparisons versus relevant alternatives across sample types and downstream assays (e.g., recovery, analyte stability, matrix effects, interference, reproducibility). Until such data exist, keep human clinical and review context separate from reagent performance claims.

    FAQ

    • Does this packet contain bench evidence that dilute acetic acid improves peptide solubilization or LC–MS performance?
    • No. Within this packet, there are no primary bench studies directly testing dilute acetic acid performance in peptide/proteomics workflows [pubmed:31472480; pubmed:38117889; pubmed:38359688].
    • Can the acetic acid standards/monographs here be used to infer protocol concentrations or efficacy in peptide workflows?
    • Not from this packet. They specify grades and properties, but do not validate concentration–performance relationships for peptide applications [crossref:10.3403/30305818; crossref:10.1021/acsreagents.4003.20160601; crossref:10.1021/acsreagents.4003.20250401].
    • Are any included human clinical data relevant to using dilute acetic acid as a lab reagent?
    • No. The clinical items address propolis in hemodialysis patients and vinegar ingestion effects on metabolism—neither evaluates laboratory reagent performance [pubmed:39453192; pubmed:28292654].
    • Do the engineering papers on biomass hydrolysis or reactive distillation inform peptide reagent use?
    • No. They address process engineering contexts and do not test peptide or proteomics workflows [crossref:10.1021/acssuschemeng.1c02937.s001; crossref:10.58837/chula.the.2006.1639].
    • Should methods or informatics papers in this packet be treated as efficacy evidence for dilute acetic acid in proteomics?
    • No. These are context-only and do not establish reagent efficacy [pubmed:31472480; pubmed:38117889; pubmed:38359688].

    References

    • Clinical / human: [pubmed:39453192] https://pubmed.ncbi.nlm.nih.gov/39453192/
    • Reviews / context: [pubmed:28292654] https://pubmed.ncbi.nlm.nih.gov/28292654/; [pubmed:30074030] https://pubmed.ncbi.nlm.nih.gov/30074030/; [pubmed:16202844] https://pubmed.ncbi.nlm.nih.gov/16202844/; [pubmed:36985356] https://pubmed.ncbi.nlm.nih.gov/36985356/
    • Preclinical / methods / informatics: [pubmed:31472480] https://pubmed.ncbi.nlm.nih.gov/31472480/; [pubmed:38117889] https://pubmed.ncbi.nlm.nih.gov/38117889/; [pubmed:38359688] https://pubmed.ncbi.nlm.nih.gov/38359688/
    • Engineering / processing: [crossref:10.1021/acssuschemeng.1c02937.s001] https://doi.org/10.1021/acssuschemeng.1c02937.s001; [crossref:10.58837/chula.the.2006.1639] https://doi.org/10.58837/chula.the.2006.1639
    • Standards / monographs: [crossref:10.3403/30305818] https://doi.org/10.3403/30305818; [crossref:10.1021/acsreagents.4003.20160601] https://doi.org/10.1021/acsreagents.4003.20160601; [crossref:10.1021/acsreagents.4003.20250401] https://doi.org/10.1021/acsreagents.4003.20250401
    • Additional screened (unrelated to reagent performance): [pubmed:32360535] https://pubmed.ncbi.nlm.nih.gov/32360535/; [pubmed:34225007] https://pubmed.ncbi.nlm.nih.gov/34225007/; [pubmed:36494624] https://pubmed.ncbi.nlm.nih.gov/36494624/; [pubmed:3379315] https://pubmed.ncbi.nlm.nih.gov/3379315/
    • Patent listings (non-evidentiary): [patent_search:dilute-acetic-acid-peptide-solubilization-laboratory-reagent] https://patents.google.com/?q=dilute+acetic+acid+peptide+solubilization+laboratory+reagent

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About ARA-290?

    What Does the Published Research Say About ARA‑290 (cibinetide)?

    Research Context

    • Scope: This summary is limited to the sources in the synthesis packet and separates direct human evidence, review-context literature, and preclinical/mechanistic findings. Citation markers refer to the supplied items (e.g., [pubmed:29392190]).
    • Evidence map (from the packet): 1 human-source item, 3 review items, and 8 preclinical or related items. The strongest conclusions should remain tied to the specific human context studied.

    Key Takeaway

    Human evidence for ARA‑290 (cibinetide) is limited and neuropathy-focused. Most reported effects come from preclinical models; mechanism centers on innate repair receptor (IRR) engagement, which does not by itself establish clinical efficacy.

    Direct Answer

    • Direct human-source evidence exists but is narrow and neuropathy-focused; conclusions should remain anchored to the specific populations, endpoints, and disease contexts actually studied [pubmed:29392190].
    • Mechanistically, ARA‑290 targets the innate repair receptor (IRR), a heteromer of the erythropoietin receptor and the β‑common (CD131) receptor, with signaling linked to anti‑inflammatory and tissue‑repair pathways [pubmed:29392190].
    • Reviews provide mechanistic and translational framing but do not substitute for primary human outcome data [pubmed:39996752; pubmed:28652140; pubmed:33423557].
    • Multiple preclinical studies report model‑specific effects (e.g., neuroinflammation, ischemia, nerve injury, SLE, chemotherapy‑related genotoxicity), which should not be presented as established human outcomes [pubmed:29570934; pubmed:36046815; pubmed:38488446; pubmed:40216181; pubmed:32335150].
    • Dosing, safety, and broad clinical recommendations are not established by the supplied sources (packet uncertainties).

    Direct Human Evidence

    • The packet includes a single human‑source citation focused on neuropathy that characterizes the IRR as a heteromer of EPOR and the β‑common (CD131) receptor and links its activation to anti‑inflammatory and tissue‑repair signaling [pubmed:29392190].
    • Importantly, this item primarily functions as review/context rather than reporting primary trial outcomes. It contains the packet’s only human‑level information and should not be overinterpreted as robust clinical efficacy evidence. Conclusions should not be generalized beyond the studied neuropathy context and endpoints [pubmed:29392190].

    Review Literature and Context

    • Reviews in the packet summarize erythropoietin biology and related translational topics, providing context but not primary outcome evidence:
    • Erythropoietin’s canonical role in erythropoiesis and broader regulatory considerations are covered in overviews [pubmed:39996752; pubmed:28652140]. These reviews are not specific to ARA‑290 clinical outcomes.
    • The translational challenges and unmet need in neuropathy are reviewed, relevant to considering targets like IRR/ARA‑290 [pubmed:33423557].
    • These reviews help frame mechanistic plausibility and clinical rationale but do not establish clinical efficacy [pubmed:39996752; pubmed:28652140; pubmed:33423557].

    Preclinical and Mechanistic Findings (Animal/In Vitro)

    • ARA‑290‑specific models:
    • Murine chronic stress: ARA‑290 ameliorated depression‑like behavior and reduced inflammation in mice [pubmed:36046815].
    • Murine cerebral ischemia: ARA‑290 mediated brain tissue protection via the β‑common receptor in a stroke model [pubmed:38488446].
    • Schwann cell/sciatic nerve injury (preclinical, 2025): ARA‑290 inhibited NLRP3 inflammasome activation in Schwann cells after sciatic nerve injury [pubmed:40216181].
    • Chemotherapy injury (preclinical): ARA‑290 attenuated doxorubicin‑induced genotoxicity and oxidative stress in experimental systems [pubmed:32335150].
    • EPO‑derived peptide models not necessarily specifying ARA‑290:
    • Systemic lupus erythematosus (murine): a non‑erythropoietic EPO‑derived peptide protected mice in an SLE model [pubmed:29570934].
    • Important caveat: These findings are model‑ and context‑specific. They provide mechanistic hypotheses and translational signals but do not establish human clinical efficacy.

    Peripheral or Reference Materials in the Packet

    • General reference resources: a PubChem compound record for cibinetide and a patent‑search entry are listed for background/reference and do not substantiate delivery, stability, or design claims [pubchem:91810664; patent_search:ara-290-cibinetide-helix-b-surface-peptide].
    • Peptide/helix design references provide general background on peptide architectures and are not ARA‑290 clinical or delivery studies [crossref:10.1007/springerreference_35417; crossref:10.1007/springerreference_33352; crossref:10.1007/3-540-29623-9_7284; crossref:10.1021/ja061989d.s001; crossref:10.1021/jacs.5c04078.s001].
    • Other packet items with peripheral relevance and not directly focused on ARA‑290 include a delivery system for pain relief in experimental neuropathy [pubmed:27028159], a bioengineered nanoreactor for radiation‑induced lung injury [pubmed:34478930], and a review on macrophage efferocytosis in apical periodontitis [pubmed:38612664]. These do not provide direct clinical evidence for ARA‑290.

    What Is Not Established (Explicit Cautions)

    • Clinical efficacy beyond the specific human populations and endpoints actually studied is not supported by this packet [pubmed:29392190].
    • Translation of preclinical findings to human outcomes is uncertain; animal/in vitro results should not be reframed as proven clinical efficacy [pubmed:29570934; pubmed:36046815; pubmed:38488446; pubmed:40216181; pubmed:32335150].
    • Dosing, safety, and generalized clinical recommendations are not established by the supplied sources (packet uncertainties).
    • Broad claims (e.g., anti‑aging; generalized tissue repair across indications) are unsupported by the present evidence base; mechanistic plausibility alone does not establish clinical utility (packet unsupported claims).

    Practical Notes for Researchers

    • The literature in this packet is review‑heavy relative to primary human studies; prioritize primary human outcome data when forming clinical or regulatory conclusions.
    • Preclinical signals highlight mechanistic axes (IRR signaling via β‑common/CD131; inflammasome modulation; anti‑inflammatory and tissue‑protective phenotypes) that may justify targeted translational studies. Each requires clinical validation before therapeutic claims are made [pubmed:29392190; pubmed:36046815; pubmed:38488446; pubmed:40216181; pubmed:32335150].

    FAQ

    • What is ARA‑290 (cibinetide) and how is it thought to work?
    • It is a non‑erythropoietic erythropoietin‑derived peptide that targets the innate repair receptor (IRR), a heteromer of EPOR and β‑common (CD131), linked to anti‑inflammatory and tissue‑repair signaling [pubmed:29392190].
    • What human evidence exists for ARA‑290?
    • The packet contains one neuropathy‑focused human‑source item that primarily serves as review/context with limited human‑level information; it should not be treated as robust clinical efficacy evidence [pubmed:29392190].
    • What do preclinical studies suggest?
    • Model‑specific signals include effects in murine depression‑like behavior, murine cerebral ischemia, Schwann cell inflammasome modulation after nerve injury, and attenuation of doxorubicin‑related genotoxicity [pubmed:36046815; pubmed:38488446; pubmed:40216181; pubmed:32335150]. These are not established human outcomes.
    • Do the reviews in the packet demonstrate clinical efficacy for ARA‑290?
    • No. They provide mechanistic and translational context (e.g., EPO biology, neuropathy unmet needs) and do not establish ARA‑290 clinical outcomes [pubmed:39996752; pubmed:28652140; pubmed:33423557].
    • Does the packet support dosing or safety conclusions for ARA‑290?
    • No. Dosing, safety, and broad clinical recommendations are not established by the supplied sources (packet uncertainties).

    References

    • [pubmed:29392190] Targeting the innate repair receptor to treat neuropathy. https://pubmed.ncbi.nlm.nih.gov/29392190/
    • [pubmed:39996752] The Role of Erythropoietin in Metabolic Regulation. https://pubmed.ncbi.nlm.nih.gov/39996752/
    • [pubmed:28652140] Erythropoietin in diabetic retinopathy. https://pubmed.ncbi.nlm.nih.gov/28652140/
    • [pubmed:33423557] The time to develop treatments for diabetic neuropathy. https://pubmed.ncbi.nlm.nih.gov/33423557/
    • [pubmed:29570934] Non‑erythropoietic erythropoietin‑derived peptide protects mice from systemic lupus erythematosus. https://pubmed.ncbi.nlm.nih.gov/29570934/
    • [pubmed:36046815] Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress‑Induced Depression‑Like Behavior and Inflammation in Mice. https://pubmed.ncbi.nlm.nih.gov/36046815/
    • [pubmed:38488446] Erythropoietin‑derived peptide ARA290 mediates brain tissue protection through the β‑common receptor in mice with cerebral ischemic stroke. https://pubmed.ncbi.nlm.nih.gov/38488446/
    • [pubmed:40216181] ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury. https://pubmed.ncbi.nlm.nih.gov/40216181/
    • [pubmed:32335150] An engineered non‑erythropoietic erythropoietin‑derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. https://pubmed.ncbi.nlm.nih.gov/32335150/
    • [pubchem:91810664] PubChem compound record: Cibinetide. https://pubchem.ncbi.nlm.nih.gov/compound/91810664
    • [patent_search:ara-290-cibinetide-helix-b-surface-peptide] Google Patents search for ARA‑290 cibinetide helix B surface peptide. https://patents.google.com/?q=ARA-290+cibinetide+helix+B+surface+peptide
    • [crossref:10.1007/springerreference_35417] Helix Initiation Peptide Helix Termination Peptide. https://doi.org/10.1007/springerreference_35417
    • [crossref:10.1007/springerreference_33352] Helix Termination Peptide. https://doi.org/10.1007/springerreference_33352
    • [crossref:10.1007/3-540-29623-9_7284] Helix Initiation Peptide Helix Termination Peptide (2005). https://doi.org/10.1007/3-540-29623-9_7284
    • [crossref:10.1021/ja061989d.s001] Helix Triangle: Unique Peptide‑Based Molecular Architecture. https://doi.org/10.1021/ja061989d.s001
    • [crossref:10.1021/jacs.5c04078.s001] Metal‑‑Helix Peptide Frameworks. https://doi.org/10.1021/jacs.5c04078.s001
    • [pubmed:27028159] Mesoporous Silica Particles as a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy. https://pubmed.ncbi.nlm.nih.gov/27028159/
    • [pubmed:34478930] Multifaceted roles of a bioengineered nanoreactor in repressing radiation‑induced lung injury. https://pubmed.ncbi.nlm.nih.gov/34478930/
    • [pubmed:38612664] The Role of Macrophage Efferocytosis in the Pathogenesis of Apical Periodontitis. https://pubmed.ncbi.nlm.nih.gov/38612664/

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About 5-Amino-1MQ?

    What Does the Published Research Say About 5‑Amino‑1MQ?

    Research Context

    • Topic focus: 5‑Amino‑1‑methylquinolinium (5‑Amino‑1MQ) appears in this packet as a chemical entity with a registry listing and a patent‑search record. The PubChem entry is a registry record (not functional validation) [pubchem:950107]. The patent‑search record indicates filings that propose 5‑Amino‑1MQ as an NNMT inhibitor scaffold; patents are not clinical evidence [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].
    • Evidence composition: human observational/biomarker studies related to NNMT in disease contexts, review literature on NNMT biology and translational interest, and preclinical reports on NNMT inhibition and structure–activity relationships (SAR) [pubmed:39067875; pubmed:37576910; pubmed:34029690; pubmed:33453420; pubmed:35756670; pubmed:32389809; pubmed:40484359; pubmed:41543936; pubmed:37523719; pubmed:29320176; pubmed:36622754; pubmed:31589440].
    • Scope note: the packet does not include human interventional trials of 5‑Amino‑1MQ or other NNMT inhibitors. Where human data are present, they are disease‑specific, observational, and focus on NNMT rather than on 5‑Amino‑1MQ per se.

    Key Takeaway

    Published studies in this packet do not include human trials of 5‑Amino‑1MQ. Human data relate to NNMT as a disease‑associated biomarker (UBC, CKD), while NNMT inhibition evidence is limited to animal and cell models. Registry and patent listings do not establish clinical efficacy or safety.

    Direct Answer

    • No human clinical trials of 5‑Amino‑1MQ are reported in the supplied literature. Human findings address NNMT associations in specific diseases (urothelial bladder cancer; chronic kidney disease) and should not be generalized as therapeutic efficacy [pubmed:39067875; pubmed:37576910].
    • NNMT inhibition has been studied preclinically (animal and cell models) across cardiac, liver, kidney, and oncology‑relevant contexts; these are not established human outcomes [pubmed:40484359; pubmed:32389809; pubmed:41543936; pubmed:36622754].
    • The packet provides a chemical registry entry and patent‑search context for 5‑Amino‑1MQ but no human dosing, safety, or efficacy data [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].

    Human evidence (observational/associational; not interventional)

    • Urothelial bladder cancer (UBC): NNMT in cancer‑associated fibroblasts is linked to tumor progression and resistance to immunotherapy, with mechanistic work alongside analyses in human UBC cohorts [pubmed:39067875].
    • Chronic kidney disease (CKD): NNMT is reported as a predictive marker of tubular fibrosis in human CKD cohorts [pubmed:37576910].
    • Interpretation boundaries: These studies inform NNMT’s disease associations and potential biomarker roles. They do not establish therapeutic benefit of NNMT inhibition or of 5‑Amino‑1MQ in humans [pubmed:39067875; pubmed:37576910].

    Review context (mechanistic framing; not a substitute for outcomes)

    • Reviews summarize NNMT’s catalytic role (methylation of nicotinamide to 1‑methylnicotinamide), its intersections with cellular metabolism and epigenetic regulation, and its potential as a biomarker/target across diseases [pubmed:34029690; pubmed:33453420; pubmed:35756670]. Mechanistic plausibility does not establish clinical utility.

    Preclinical evidence and chemical tools (non‑human)

    • Liver/metabolism: ER stress–induced NNMT upregulation contributes to alcohol‑related fatty liver development in preclinical models [pubmed:32389809].
    • Cardiac (mouse): NNMT inhibition improved cardiac structure and function in a heart‑failure‑with‑preserved‑ejection‑fraction mouse model [pubmed:40484359].
    • Kidney (non‑human): NNMT inhibition counteracted tubular senescence and fibrosis in early‑stage CKD models [pubmed:41543936].
    • Oncology/mechanisms (preclinical systems): m6A RNA modifications regulated chemotherapy response via NNMT [pubmed:36622754].
    • Chemical probes/SAR: discovery and optimization of NNMT bisubstrate and high‑affinity inhibitors, including cell‑potent tools, define tractable scaffolds and structure–activity relationships; these published inhibitor series are distinct from 5‑Amino‑1MQ and should not be cross‑extrapolated [pubmed:29320176; pubmed:31589440; pubmed:37523719].
    • Translation note: Animal/cell findings and chemical‑tool potency are not evidence of human clinical benefit or safety [pubmed:32389809; pubmed:40484359; pubmed:41543936; pubmed:29320176; pubmed:31589440; pubmed:37523719; pubmed:36622754].

    Chemical identity and patent context for 5‑Amino‑1MQ

    • Chemical registry: 5‑Amino‑1‑methylquinolinium is indexed in PubChem as a compound record; the listing itself does not validate function or therapeutic use [pubchem:950107].
    • Intellectual property: A patent‑search record lists filings/applications that propose 5‑Amino‑1MQ as an NNMT inhibitor scaffold. Such records signal research interest but do not substitute for peer‑reviewed human efficacy or safety data [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].

    Limitations and open questions from this packet

    • No human interventional data for 5‑Amino‑1MQ or any NNMT inhibitor are presented.
    • Human findings are disease‑specific observational/biomarker associations (UBC; CKD) and should not be extrapolated to other conditions without new data [pubmed:39067875; pubmed:37576910].
    • Dosing, safety, and generalized risk profiles in humans are not addressed by this packet.
    • A substantial share of the evidence is preclinical, limiting translational certainty.

    FAQ

    • Is 5‑Amino‑1MQ clinically studied in humans?
    • No human clinical trials of 5‑Amino‑1MQ are included in the supplied literature. The packet provides only a registry entry and a patent‑search record for this compound [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].
    • What human evidence exists around NNMT?
    • Observational studies link NNMT to tumor progression and immunotherapy resistance in urothelial bladder cancer and identify NNMT as a predictive marker of tubular fibrosis in CKD; these are not intervention trials and do not demonstrate therapeutic benefit [pubmed:39067875; pubmed:37576910].
    • What do animal and cell studies suggest about NNMT inhibition?
    • NNMT inhibition improved cardiac structure/function in a mouse HFpEF model, mitigated tubular senescence/fibrosis in CKD models, and mechanistic work connected NNMT to chemotherapy response; these are preclinical findings [pubmed:40484359; pubmed:41543936; pubmed:36622754].
    • Are the published NNMT inhibitor chemotypes the same as 5‑Amino‑1MQ?
    • No. The SAR series (bisubstrate and related high‑affinity inhibitors) are distinct chemotypes and should not be directly cross‑extrapolated to 5‑Amino‑1MQ [pubmed:29320176; pubmed:31589440; pubmed:37523719].
    • Does a registry or patent entry validate 5‑Amino‑1MQ as a therapy?
    • No. A PubChem listing is a registry record, and patent filings reflect intellectual property activity; neither is evidence of clinical efficacy or safety [pubchem:950107; patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor].

    References

    • [pubmed:39067875] NAD(+) metabolism enzyme NNMT in cancer‑associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. https://pubmed.ncbi.nlm.nih.gov/39067875/
    • [pubmed:40484359] Nicotinamide‑N‑methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model. https://pubmed.ncbi.nlm.nih.gov/40484359/
    • [pubmed:41543936] NNMT inhibition counteracts tubular senescence and fibrosis in early stages of chronic kidney disease. https://pubmed.ncbi.nlm.nih.gov/41543936/
    • [pubmed:34029690] Nicotinamide N‑methyl transferase (NNMT): An emerging therapeutic target. https://pubmed.ncbi.nlm.nih.gov/34029690/
    • [pubmed:33453420] Nicotinamide N‑methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation. https://pubmed.ncbi.nlm.nih.gov/33453420/
    • [pubmed:37523719] Structure‑Activity Relationship Studies on Cell‑Potent Nicotinamide N‑Methyltransferase Bisubstrate Inhibitors. https://pubmed.ncbi.nlm.nih.gov/37523719/
    • [pubmed:35756670] Nicotinamide N‑Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy. https://pubmed.ncbi.nlm.nih.gov/35756670/
    • [pubmed:37576910] Nicotinamide N‑Methyl Transferase as a Predictive Marker of Tubular Fibrosis in CKD. https://pubmed.ncbi.nlm.nih.gov/37576910/
    • [pubmed:29320176] Discovery of Bisubstrate Inhibitors of Nicotinamide N‑Methyltransferase (NNMT). https://pubmed.ncbi.nlm.nih.gov/29320176/
    • [pubmed:36622754] N6‑Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N‑methyltransferase. https://pubmed.ncbi.nlm.nih.gov/36622754/
    • [pubmed:31589440] High‑Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide N‑Methyltransferase (NNMT). https://pubmed.ncbi.nlm.nih.gov/31589440/
    • [pubchem:950107] PubChem compound record: 5‑Amino‑1‑methylquinolinium. https://pubchem.ncbi.nlm.nih.gov/compound/950107
    • [patent_search:5-amino-1mq-5-amino-1-methylquinolinium-nnmt-inhibitor] Google Patents search for 5‑Amino‑1MQ 5‑amino‑1‑methylquinolinium NNMT inhibitor. https://patents.google.com/?q=5-Amino-1MQ+5-amino-1-methylquinolinium+NNMT+inhibitor

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About KPV?

    Research Context

    • The packet comprises four human-study sources, one review, and several preclinical reports (cell, animal, and delivery/formulation). The human-study sources in this packet are not KPV intervention trials and do not establish KPV-specific clinical efficacy [pubmed:36175155; pubmed:35320643; pubmed:35830641; pubmed:40935835].
    • The strongest conclusions should remain anchored to the specific populations/endpoints actually studied; do not generalize beyond those contexts. Parts of the evidence base are preclinical, limiting translational certainty.
    • Dosing and systemic safety are not established by this packet and should not be inferred.

    Evidence map (packet-level):

    • Human-study sources: 4 (not KPV interventions)
    • Review sources: 1 (contextual, not KPV-specific efficacy)
    • Preclinical sources: multiple (in vitro, animal, delivery/formulation, structural/materials)

    Key Takeaway

    Most evidence for KPV in this packet is preclinical. There are no KPV-specific human interventional outcomes here; mechanistic cell studies, animal models, and delivery work should not be interpreted as clinical efficacy, dosing guidance, or safety evidence.

    Direct Answer

    • This packet provides no KPV-specific human interventional outcome data. Available findings are predominantly preclinical: in vitro anti-inflammatory signaling, animal-model barrier findings using a KPV-binding hydrogel, transdermal and colon-targeted delivery studies, and peptide self-assembly/nanomaterial work [pubmed:40073467; pubmed:22837805; pubmed:35245681; pubmed:19909746; pubmed:28343991; pubmed:39252648].
    • Review content offers disease-context framing but is not evidence of KPV efficacy [pubmed:28806188]. Bottom line: human efficacy for KPV is not established in this packet.

    Human Evidence in the Packet (Context Only; Not KPV Trials)

    • [pubmed:36175155] International consensus recommendations for adrenoleukodystrophy (ALD) diagnosis/management. Not a KPV study; no KPV interventional outcomes.
    • [pubmed:35320643] Hydrocortisone in preterm infants (survival without bronchopulmonary dysplasia). Not a KPV study; no KPV interventional outcomes.
    • [pubmed:35830641] Erythropoietin trial for neonatal hypoxic-ischemic encephalopathy. Not a KPV study; no KPV interventional outcomes.
    • [pubmed:40935835] Mechanistic work on NLRP3 autophagic degradation disruption in melanocytes relevant to vitiligo pathobiology. This is disease-mechanistic context, not a KPV intervention or clinical outcome study.

    Interpretation: These human-study citations are included in the packet but do not establish KPV clinical efficacy. Conclusions regarding KPV should not be extrapolated from these unrelated human studies.

    Review Context (Not KPV-Specific)

    • [pubmed:28806188] Review of tubulointerstitial nephritis and uveitis (TINU). Provides context on ocular inflammatory mechanisms/disease but is not about KPV and should not be used as evidence of KPV efficacy.

    Preclinical and Mechanistic Evidence

    • In vitro (cellular) findings
    • [pubmed:40073467] In vitro human keratinocyte culture: KPV mitigated fine dust–induced apoptosis and inflammatory signaling by regulating oxidative stress and modulating MAPK/NF-κB pathways.
    • [pubmed:22837805] In vitro human bronchial epithelial cells: melanocortin-related peptides (including KPV-related mechanisms) inhibited inflammatory cues; implicated MC3R-related pathways. These are mechanistic cellular data, not clinical outcomes.
    • Animal models and tissue-level preclinical work
    • [pubmed:35245681] A KPV-binding double-network hydrogel restored gut mucosal barrier measures in an inflamed colon mouse model (animal study). No human outcomes were evaluated.
    • [pubmed:19909746] Colon-targeted drug-loaded nanoparticles within polysaccharide hydrogels reduced colitis severity in a mouse model (preclinical delivery concept relevant to peptide interventions). Not KPV-specific efficacy.
    • Delivery/formulation and nanomaterials
    • [pubmed:28343991] Transdermal iontophoretic delivery of KPV across ex vivo microporated human skin demonstrated permeation under iontophoresis (delivery/permeation study). This is not evidence of systemic exposure or clinical efficacy.
    • [pubmed:39252648] KPV and rapamycin self-assembled into carrier-free nanodrugs evaluated for vascular calcification therapy in preclinical systems (nanomaterials/preclinical; no human outcomes).
    • Structural/materials and related context
    • [crossref:10.1211/0022357011776360] Conformational analysis of Ac-Lys-Pro-Val-NH2 (KPV motif) provides structural context (structural/biophysical; not efficacy).
    • [crossref:10.1021/acs.biomac.5c01800.s001] Self-assembly of Pro-Val-Pro-Val into nanoporous peptide frameworks (materials science; not KPV-specific efficacy).
    • [crossref:10.1271/bbb.80473] Transepithelial transport characteristics of a non-KPV antihypertensive hexapeptide in Caco-2 monolayers (analog/transport context; not KPV-specific).
    • [pubchem:125672] Compound record for MSH(11–13) fragment (Lys-Pro-Val/KPV) (database record; structural/identifier context).
    • [crossref:10.1021/acs.jafc.3c02918.s001] Neuroprotection/gut microbiota study of a selenopeptide distinct from KPV (non-KPV; excluded from efficacy discussion).
    • Unrelated preclinical citation included in the packet
    • [pubmed:37161053] Vimentin required for tumor progression/metastasis in a mouse NSCLC model (preclinical/oncology). This study is unrelated to KPV and should not be interpreted as informing KPV.

    Limitations and Uncertainties

    • No KPV-specific human interventional outcome trials are present in the packet; clinical efficacy for any indication is not established here.
    • Dosing, systemic exposure, and safety are not resolved by the packet and should not be inferred.
    • Preclinical (cell/animal) and delivery/formulation findings may be mechanistically or translationally interesting but do not constitute human clinical outcomes.
    • Mechanistic plausibility or materials advances should not be reframed as proven clinical benefit without appropriately designed human trials.

    Bottom line: based on this packet, KPV lacks established human efficacy, and no dosing or safety conclusions can be drawn.

    FAQ

    • Are there any human trials showing KPV works for a specific condition?
    • No. This packet contains no KPV-specific human interventional outcomes [pubmed:36175155; pubmed:35320643; pubmed:35830641; pubmed:40935835].
    • What mechanisms has KPV shown in lab studies?
    • In vitro, KPV reduced oxidative stress–linked apoptosis and inflammatory signaling in human keratinocytes and modulated MAPK/NF-κB; melanocortin-related peptides also inhibited inflammatory cues in human bronchial epithelial cells with a role for MC3R [pubmed:40073467; pubmed:22837805].
    • Are there animal data relevant to KPV?
    • A KPV-binding hydrogel improved gut barrier measures in an inflamed colon mouse model; colon-targeted nanoparticle hydrogels reduced colitis in mice (not KPV-specific) [pubmed:35245681; pubmed:19909746]. These are preclinical findings only.
    • Does KPV cross the skin or target the vasculature based on current studies?
    • Ex vivo iontophoretic delivery showed KPV permeation across microporated human skin (delivery study), and KPV co-assembled with rapamycin into nanodrugs evaluated preclinically for vascular calcification; neither demonstrates human exposure or efficacy [pubmed:28343991; pubmed:39252648].
    • Does this packet inform dosing or safety for KPV?
    • No. The packet does not establish dosing, systemic exposure, or safety for KPV.

    References

    • Human-study/context citations: [pubmed:36175155]; [pubmed:35320643]; [pubmed:35830641]; [pubmed:40935835].
    • Review (context only): [pubmed:28806188].
    • Preclinical in vitro/cellular: [pubmed:40073467]; [pubmed:22837805].
    • Preclinical animal/tissue-level: [pubmed:35245681]; [pubmed:19909746].
    • Delivery/formulation/nanomaterials: [pubmed:28343991]; [pubmed:39252648].
    • Structural/materials/records: [crossref:10.1211/0022357011776360]; [crossref:10.1021/acs.biomac.5c01800.s001]; [crossref:10.1271/bbb.80473]; [pubchem:125672]; [crossref:10.1021/acs.jafc.3c02918.s001] (non-KPV).

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About GHK-Cu?

    What Does the Published Research Say About GHK‑Cu?

    Research Context

    • The supplied packet contains one human/clinical study, several review articles, and multiple preclinical/mechanistic reports. Conclusions below are limited to the packet and its uncertainties.
    • Reviews are used to frame mechanisms and translational hypotheses; they do not substitute for primary human outcome evidence [pubmed:29986520; pubmed:35083444; pubmed:26236730; pubmed:39963574; pubmed:41490200; pubmed:41476424].
    • Animal, in vitro, and biochemical findings are separated from human conclusions and should not be presented as established clinical outcomes.
    • The human/clinical label for the cited study follows the packet’s classification; study design specifics (e.g., endpoints, randomization) are not provided here.

    Key Takeaway

    Direct human evidence is narrow (smoke‑related skeletal muscle dysfunction). Broader “regenerative” or “anti‑aging” narratives are review‑driven or preclinical and remain hypothesis‑generating.

    Direct Answer

    • Human evidence in this packet is limited to one study in the context of cigarette smoke–related skeletal muscle dysfunction; a SIRT1‑dependent pathway is proposed but not established as causal in humans [pubmed:36905132].
    • Broader narratives about regeneration, dermatology, or anti‑aging are largely review‑driven and supported by preclinical models; they are hypothesis‑generating rather than confirmatory [pubmed:29986520; pubmed:35083444; pubmed:26236730; pubmed:39963574; pubmed:41490200; pubmed:41476424].
    • The packet does not justify dosing or generalized safety conclusions.

    Human evidence (primary)

    • One study classified in the packet as human/clinical addresses GHK‑Cu in a cigarette smoking–related skeletal muscle dysfunction context and reports effects in that setting. The authors propose a SIRT1‑dependent pathway, which should be treated as an associated/proposed mechanism rather than confirmed human causality based on the packet alone. Specific endpoints and cohort details are not provided in the packet and are therefore not extrapolated here [pubmed:36905132].

    Review (context)

    • Reviews synthesize mechanistic and translational themes for GHK and GHK‑Cu, including regenerative/protective actions and potential relevance to skin biology and aging; these do not replace primary human outcome data [pubmed:29986520; pubmed:35083444; pubmed:26236730; pubmed:39963574].
    • Two reviews serve as broader overviews of peptide therapies (orthopaedic and injectable therapy primers) rather than GHK‑specific clinical outcome syntheses; they are used here for general context only [pubmed:41490200; pubmed:41476424].
    • Age‑related serum GHK level figures (e.g., ~200 ng/mL at ~20 years, ~80 ng/mL at ~60 years) are review‑derived and should not be treated as definitive population surveillance; they are not used to draw clinical conclusions here [pubmed:35083444].

    Preclinical and mechanistic evidence

    • Pulmonary models
    • Silicosis model: attenuation of lung inflammation and fibrosis with a proposed PRDX6 target [pubmed:38879894].
    • Cigarette smoke–induced emphysema/inflammation: effects associated with oxidative‑stress pathways [pubmed:35936787].
    • Gastrointestinal model
    • Experimental colitis: reports of beneficial effects with mechanistic exploration [pubmed:40672369].
    • Zebrafish inflammation model
    • Attenuation of CuSO4 or LPS‑induced inflammation in larvae [pubmed:41997403; crossref:10.1016/j.ejphar.2026.178880].
    • Biomaterials/local delivery (experimental)
    • GHK‑Cu loaded into hydroxyapatite microspheres for localized anti‑inflammatory/antioxidant purposes in experimental systems [pubmed:40716276].
    • Chemistry and binding (biochemical/in vitro)
    • Copper(II) binding to GHK (DFT study) [crossref:10.22144/ctu.jen.2018.052].
    • Fluorescent chemosensor development based on GHK [crossref:10.1021/ol0101638; crossref:10.1002/chin.200208210].
    • Stimulation of sulfated glycosaminoglycan synthesis by GHK‑Cu (biochemical context) [crossref:10.1016/0024-3205(92)90504-i].
    • Identity and records (ancillary)
    • PubChem compound entry for GHK [pubchem:73587].
    • Patent search indicating commercial interest; not efficacy evidence [patent_search:ghk-cu-copper-tripeptide-1-glycyl-l-histidyl-l-lysine].

    Limitations and open questions

    • Translational certainty remains limited: animal/in vitro findings do not establish human efficacy [pubmed:38879894; pubmed:35936787; pubmed:41997403; pubmed:40672369; pubmed:40716276].
    • Human evidence is sparse and context‑specific; conclusions should remain anchored to the smoking‑related skeletal muscle dysfunction domain studied [pubmed:36905132].
    • Reviews provide useful context but cannot substitute for clinical outcome trials [pubmed:29986520; pubmed:35083444; pubmed:26236730; pubmed:39963574; pubmed:41490200; pubmed:41476424].
    • Dosing, safety, and generalizability are not established by the supplied evidence.
    • Because copper binding alters peptide chemistry, findings for GHK versus GHK‑Cu may not be interchangeable across studies; check the form investigated in each report [crossref:10.22144/ctu.jen.2018.052; crossref:10.1021/ol0101638; crossref:10.1016/0024-3205(92)90504-i].

    FAQ

    • What human clinical evidence exists for GHK‑Cu?
    • The packet includes one human/clinical study focused on cigarette smoke–related skeletal muscle dysfunction; a SIRT1‑dependent mechanism is proposed but not confirmed as causal in humans [pubmed:36905132].
    • Does the literature support anti‑aging or cosmetic efficacy in humans?
    • Not in this packet. These narratives are largely review‑driven or based on preclinical work; primary human outcome trials are not provided here [pubmed:39963574; pubmed:29986520; pubmed:35083444; pubmed:26236730].
    • What do preclinical models report about GHK‑Cu?
    • Reports include attenuation of lung inflammation/fibrosis in silicosis models [pubmed:38879894], mitigation of cigarette smoke–induced emphysema/inflammation [pubmed:35936787], beneficial effects in experimental colitis [pubmed:40672369], and reduced inflammation in zebrafish larvae exposed to CuSO4 or LPS [pubmed:41997403]. These findings are not established human outcomes.
    • Are GHK and GHK‑Cu findings interchangeable across studies?
    • Not necessarily. Copper binding changes peptide interactions; studies distinguish between GHK and GHK‑Cu, and results may differ by form and context [crossref:10.22144/ctu.jen.2018.052; crossref:10.1021/ol0101638; crossref:10.1016/0024-3205(92)90504-i].
    • Are dosing or generalized safety conclusions available?
    • No. The packet does not provide sufficient primary human outcome data to support dosing guidance or generalized safety conclusions.

    References

    • Human/clinical
    • pubmed:36905132 — https://pubmed.ncbi.nlm.nih.gov/36905132/
    • Reviews (context)
    • pubmed:29986520 — https://pubmed.ncbi.nlm.nih.gov/29986520/
    • pubmed:35083444 — https://pubmed.ncbi.nlm.nih.gov/35083444/
    • pubmed:26236730 — https://pubmed.ncbi.nlm.nih.gov/26236730/
    • pubmed:39963574 — https://pubmed.ncbi.nlm.nih.gov/39963574/
    • pubmed:41490200 — https://pubmed.ncbi.nlm.nih.gov/41490200/
    • pubmed:41476424 — https://pubmed.ncbi.nlm.nih.gov/41476424/
    • Preclinical/mechanistic
    • pubmed:38879894 — https://pubmed.ncbi.nlm.nih.gov/38879894/
    • pubmed:35936787 — https://pubmed.ncbi.nlm.nih.gov/35936787/
    • pubmed:41997403 — https://pubmed.ncbi.nlm.nih.gov/41997403/
    • pubmed:40672369 — https://pubmed.ncbi.nlm.nih.gov/40672369/
    • pubmed:40716276 — https://pubmed.ncbi.nlm.nih.gov/40716276/
    • crossref:10.22144/ctu.jen.2018.052 — https://doi.org/10.22144/ctu.jen.2018.052
    • crossref:10.1021/ol0101638 — https://doi.org/10.1021/ol0101638
    • crossref:10.1002/chin.200208210 — https://doi.org/10.1002/chin.200208210
    • crossref:10.1016/0024-3205(92)90504-i — https://doi.org/10.1016/0024-3205(92)90504-i
    • Identity/records (ancillary)
    • pubchem:73587 — https://pubchem.ncbi.nlm.nih.gov/compound/73587
    • patent_search:ghk-cu-copper-tripeptide-1-glycyl-l-histidyl-l-lysine — https://patents.google.com/?q=GHK-Cu+copper+tripeptide-1+glycyl-L-histidyl-L-lysine

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About FOXO4-DRI?

    Research Context

    • The packet contains one human-context study in oncology (senescence-targeting in NSCLC radiotherapy) and multiple reviews/mechanistic papers plus several preclinical studies on FOXO4-DRI or related FOXO4 peptides.
    • Reviews and mechanistic work on cellular senescence and the FOXO4–p53 interaction provide rationale, but they do not substitute for primary human outcome evidence [pubmed:40593617; pubmed:29260442; pubmed:29471104; pubmed:29171222; pubmed:42024235].
    • Claims below are limited to what the supplied citations support and are separated by evidence tier.

    Key Takeaway

    No human trials of FOXO4-DRI are included. One NSCLC radiotherapy study targeted senescence-like fibroblasts (not FOXO4-DRI). Evidence specific to FOXO4-DRI is preclinical or mechanistic.

    Direct Answer

    • Human evidence in this packet pertains to an NSCLC radiotherapy context that targeted senescence-like fibroblasts; FOXO4-DRI was not tested [pubmed:34877934]. Any radiosensitization and reduced radiation-induced pulmonary fibrosis findings are part of that translational program and should not be assumed to be human-only outcomes.
    • For FOXO4-DRI specifically, the packet provides mechanistic and preclinical (animal/in vitro) studies indicating senolytic activity via the FOXO4–p53 axis. These do not establish human efficacy, safety, dosing, delivery, or generalized anti-aging effects.

    Human Evidence (specific to the cited population and endpoints)

    • NSCLC radiotherapy context [pubmed:34877934]
    • Study focus: targeting senescence-like fibroblasts during radiotherapy for non-small cell lung cancer.
    • As reflected in the publication title, the translational program links this approach with tumor radiosensitization and reduced radiation-induced pulmonary fibrosis across its experimental tiers.
    • FOXO4-DRI was not used; conclusions should remain confined to this NSCLC radiotherapy context.

    Review and Mechanistic Context (not human outcome evidence)

    • Mechanistic interface of FOXO4 with p53:
    • The disordered p53 transactivation domain is identified as a target of FOXO4 and of FOXO4-DRI, clarifying a proposed senolytic mechanism; this is not clinical efficacy evidence [pubmed:40593617].
    • Broader senescence and translational framing:
    • Cellular senescence in kidney aging and transplantation [pubmed:29260442; pubmed:29471104].
    • Broader aging and interventional concepts [pubmed:29171222].
    • Conceptual review on retro-inverso peptides targeting the FOXO4–p53 axis in brain aging and cognition [pubmed:42024235].

    Preclinical Evidence (animal/in vitro; model-specific and not established in humans)

    Note: In vitro findings using human-derived cells are preclinical and do not constitute clinical evidence.

    Dermal/keloid

    • FOXO4-DRI induced apoptosis in senescent human keloid fibroblasts in vitro, associated with p53 Ser15 phosphorylation changes and nuclear exclusion [pubmed:39994346].

    Reproductive/Leydig–testis

    • FOXO4-DRI reduced SASP secretion from Leydig cells and improved spermatogenesis in aged mice (in vivo) [pubmed:39025385].
    • FOXO4-DRI alleviated age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice (in vivo) [pubmed:31959736].

    Pulmonary fibrosis

    • A non-DRI FOXO4 peptide (peptide identity not specified as DRI) ameliorated bleomycin-induced pulmonary fibrosis in mice; pathway analysis implicated ECM–receptor interactions (in vivo) [pubmed:35510614].

    Vascular/endothelium

    • FOXO4-DRI regulated endothelial cell senescence via p53 signaling in preclinical endothelial models (model systems; non-clinical) [pubmed:41625068].

    Cartilage/chondrocytes

    • FOXO4-DRI selectively removed senescent cells from in vitro expanded human chondrocytes (in vitro) [crossref:10.3389/fbioe.2021.677576].

    Liver (combination context)

    • Morphological liver changes were reported in experimental animals receiving combined adribastin and FOXO4-DRI (in vivo; descriptive histology). This is not a human safety profile [crossref:10.34680/2076-8052.2023.2(131).216-222].

    Comparative senolytic (context only; not FOXO4-DRI evidence)

    • Ionophore nigericin explored as an alternative senolytic strategy in preclinical models [pubmed:36430735].

    Notes on model scope

    • Several preclinical studies involve FOXO4-DRI specifically (keloid fibroblasts, Leydig/testis, endothelial models, human chondrocytes), while others use a generic/non-DRI FOXO4 peptide (e.g., pulmonary fibrosis). Findings with non-DRI FOXO4 peptides should not be conflated with FOXO4-DRI.

    What Is Not Established by This Packet

    • No direct clinical efficacy or safety data for FOXO4-DRI in humans are provided.
    • Preclinical (animal/in vitro) results should not be treated as established human outcomes.
    • Dosing, delivery method, tolerability, adverse events, and long-term effects in humans are not addressed by the supplied citations.
    • The NSCLC radiotherapy study did not test FOXO4-DRI; its endpoints belong to a broader translational program.
    • Patent listings are included for completeness and are not used as efficacy or safety evidence.

    FAQ

    • Has FOXO4-DRI been tested in humans in this packet?
    • No. The packet provides no human trials of FOXO4-DRI. The one human-context study in NSCLC radiotherapy did not use FOXO4-DRI [pubmed:34877934].
    • What mechanism is proposed for FOXO4-DRI?
    • Mechanistic research identifies the disordered p53 transactivation domain as a target of FOXO4 and FOXO4-DRI, supporting a senolytic hypothesis [pubmed:40593617]. This is not clinical efficacy evidence.
    • Do in vitro results in human cells (e.g., chondrocytes or keloid fibroblasts) count as clinical evidence?
    • No. These are preclinical studies and do not establish outcomes in people [crossref:10.3389/fbioe.2021.677576; pubmed:39994346].
    • Are FOXO4 peptide studies interchangeable with FOXO4-DRI findings?
    • Not necessarily. Some studies use a generic/non-DRI FOXO4 peptide; those results should not be conflated with FOXO4-DRI [pubmed:35510614].
    • Does the packet address dosing, delivery, or tolerability for FOXO4-DRI in humans?
    • No. These aspects are unaddressed in the supplied literature.

    References

    Human/clinical-context

    • [pubmed:34877934]

    Review/mechanistic context

    • [pubmed:40593617]; [pubmed:29260442]; [pubmed:29471104]; [pubmed:29171222]; [pubmed:42024235]

    Preclinical (animal/in vitro)

    • [pubmed:39994346]; [pubmed:39025385]; [pubmed:31959736]; [pubmed:35510614]; [pubmed:41625068]; [crossref:10.3389/fbioe.2021.677576]; [crossref:10.34680/2076-8052.2023.2(131).216-222]; [pubmed:36430735]

    Other sources in packet (not used as efficacy or safety evidence)

    • [patent_search:foxo4-dri-foxo4-dri-peptide-senescence]

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About Follistatin-344?

    Research Context

    Follistatin is a secreted protein that binds and neutralizes activins and related TGF-β family ligands. “Follistatin-344” (FST344) refers to a 344–amino-acid isoform; however, most sources in this packet discuss follistatin generally (and sometimes follistatin-like 3, FSTL3), not isoform-specific clinical outcomes for FST344 [pubmed:9785474; pubmed:15253386; pubmed:37739334]. The packet contains:

    • Human studies in disease-specific, non-interventional contexts (FLT3/ITD acute myeloid leukemia target/biomarker work; circulating hormone profiling in steatotic liver disease; serum follistatin levels in ovarian endometriosis) [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].
    • Multiple reviews on activin/follistatin biology, signaling, inflammation/immunity, and related systems [pubmed:9785474; pubmed:10077456; pubmed:37739334; pubmed:15253386; pubmed:31322318; pubmed:21353885].
    • Preclinical/mechanistic reports (cancer cachexia pathway mapping; angiogenin-binding) [pubmed:39116208; pubmed:17991437].
    • A nonclinical PK/PD study of an engineered human follistatin variant (not FST344) [crossref:10.1124/jpet.112.0313hia].
    • Forensic/analytical detection of black-market FST344 [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

    Isoform specificity clarification: the packet does not present isoform-specific clinical data for FST344; conclusions should not assume equivalence between total follistatin, FST344, and FSTL3.

    Key Takeaway

    The supplied literature offers disease-specific human biomarker/target findings for follistatin but no interventional trials of exogenous FST344. Mechanistic reviews and preclinical studies provide context only and do not establish efficacy, safety, or dosing.

    Direct Answer

    In this packet, direct human evidence related to follistatin is narrow and disease-specific, focusing on target/biomarker work in FLT3/ITD acute myeloid leukemia, circulating hormone measurements in biopsy-proven steatotic liver disease, and serum levels in ovarian endometriosis cohorts [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1]. None of the cited human studies involve interventional administration of exogenous FST344. Mechanistic reviews describe how follistatin modulates activin/TGF-β pathways, providing context but not clinical outcomes [pubmed:9785474; pubmed:10077456; pubmed:37739334; pubmed:15253386; pubmed:31322318; pubmed:21353885]. Preclinical reports map disease-relevant pathways and protein–protein interactions, and analytical studies document detection of black-market FST344; these do not establish clinical efficacy, safety, or dosing for FST344 [pubmed:39116208; pubmed:17991437; crossref:10.1124/jpet.112.0313hia; pubmed:31758732]. Overall, any conclusions should remain anchored to the specific human populations and endpoints studied and should not be generalized.

    Human Evidence (Disease-Specific and Observational)

    • FLT3/ITD acute myeloid leukemia: A study identified follistatin as a potential therapeutic target and biomarker in FLT3/ITD AML [pubmed:32134197]. This work concerns endogenous target/biomarker identification and does not test exogenous FST344 in humans.
    • Steatotic liver disease and steatohepatitis: A multicenter observational study measured circulating hormones, including follistatin, in biopsy-proven steatotic liver disease and steatohepatitis, providing biomarker data within that specific population [pubmed:37757973]. No interventional FST344 administration was involved.
    • Ovarian endometriosis: An observational study reported high serum follistatin levels in women with ovarian endometriosis, consistent with a biomarker association rather than interventional evaluation of FST344 [crossref:10.1016/s1090-798x(10)79409-1].

    Review Context and Mechanistic Background (Not Human Outcomes)

    • Foundational biology and signaling: Reviews summarize follistatin’s binding to activins and other TGF-β family ligands and activin receptor signaling, framing potential mechanisms relevant to diverse tissues [pubmed:9785474; pubmed:15253386].
    • Vascular and metabolic context: Reviews discuss activin/follistatin in atherosclerosis and the roles of follistatin and FSTL3 in metabolic disorders [pubmed:10077456; pubmed:37739334].
    • Immune/reproductive and inflammatory context: Activins, follistatin, and immunoregulation in the epididymis, and broader roles in inflammation and immunity, are discussed in review literature [pubmed:31322318; pubmed:21353885].

    Important clarifications:

    • Isoform specificity: Most reviews address “follistatin” generally; they are not isoform-specific for FST344.
    • Distinct proteins: FSTL3 (follistatin-like 3) is mechanistically related but distinct; findings for FSTL3 are not interchangeable with those for follistatin/FST344, and differential actions between follistatin and FSTL3 have been reported [pubmed:37739334; pubmed:15451564].

    Preclinical and Analytical/Forensic Findings (Nonclinical)

    • Cachexia pathway mapping: A single-nucleus study delineated molecular pathways associated with cancer cachexia–related muscle atrophy; it did not test FST344 or establish direct follistatin effects in humans [pubmed:39116208].
    • Protein–protein interaction: Follistatin was identified as an angiogenin-binding protein, a mechanistic interaction observed outside of human outcome trials [pubmed:17991437].
    • Engineered variant PK/PD (not FST344): A pharmacokinetic/pharmacodynamic study characterized an engineered human follistatin variant in nonclinical settings; it is not FST344 and is not human interventional evidence [crossref:10.1124/jpet.112.0313hia].
    • Forensic detection: Analytical studies detected “black market” FST344 in market/seized samples, indicating detectability but not informing product quality, dosing, safety, efficacy, or prevalence [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

    What Is Not Established (Limits of This Packet)

    • No interventional human trials of exogenous FST344 are included in this packet.
    • No randomized clinical trial evidence demonstrates clinical benefit or a defined safety profile for FST344 in broad indications.
    • No dosing, delivery, or regimen guidance is supported by the supplied literature.
    • Preclinical and mechanistic plausibility do not constitute proof of human efficacy or safety.
    • Broad claims (e.g., generalized anti-aging or multi-organ benefits) are unsupported by this packet.
    • Findings for total follistatin or FSTL3 should not be assumed to apply to the specific FST344 isoform without direct evidence.
    • Forensic detection of black-market FST344 does not speak to quality control, safety, dosing, or real-world effectiveness.
    • Conclusions should remain anchored to the specific human populations and endpoints studied [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].

    FAQ

    • What is Follistatin-344 (FST344)?
    • FST344 refers to a 344–amino-acid isoform of the follistatin protein, which binds activins and related TGF-β ligands. Most literature in this packet addresses follistatin broadly rather than FST344-specific outcomes [pubmed:9785474; pubmed:15253386].
    • Are there human trials testing exogenous FST344?
    • No interventional human studies of exogenous FST344 are included in this packet.
    • What human evidence is available?
    • Observational, disease-specific studies report follistatin as a biomarker/target in FLT3/ITD AML, measure circulating follistatin in steatotic liver disease, and report higher serum levels in ovarian endometriosis; none test exogenous FST344 [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].
    • Can findings about FSTL3 be applied to FST344?
    • No. FSTL3 is distinct from follistatin and shows differential actions; its findings are not interchangeable with those for follistatin/FST344 [pubmed:15451564; pubmed:37739334].
    • Do black-market detection studies tell us anything about safety or dosing?
    • No. These analytical reports document detection of FST344 in samples but do not inform dosing, safety, efficacy, or prevalence [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

    References

    • [pubmed:32134197]
    • [pubmed:37757973]
    • [crossref:10.1016/s1090-798x(10)79409-1]
    • [pubmed:9785474]
    • [pubmed:10077456]
    • [pubmed:37739334]
    • [pubmed:15253386]
    • [pubmed:31322318]
    • [pubmed:21353885]
    • [pubmed:15451564]
    • [pubmed:39116208]
    • [pubmed:17991437]
    • [crossref:10.1124/jpet.112.0313hia]
    • [pubmed:31758732]
    • [crossref:10.1002/dta.2741]
    • [crossref:10.1002/dta.2882]

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides

  • What Does the Published Research Say About IGF1-LR3?

    This summary draws only from the supplied synthesis packet and keeps human evidence, preclinical results, and mechanistic findings distinct. Claims are limited to what the cited studies support.

    Research Context

    • The packet is driven by animal, in vitro, and tissue-engineering studies; it does not include human clinical outcome trials for LR3 IGF-1 or native IGF-1. The packet advises against broad human-efficacy framing.
    • Several findings concern native IGF-1 rather than LR3 IGF-1; results are context-dependent across analogue, species, age, route, and delivery format. Findings for IGF-1 and LR3 should not be treated as interchangeable.

    Key Takeaway

    Published IGF-1 LR3 evidence is primarily preclinical and model-specific. Some studies report biomarker or tissue changes, but there are no human efficacy or safety outcomes in this packet, and translational relevance remains uncertain.

    Direct Answer

    • Direct human efficacy or safety evidence for IGF-1 LR3 is absent in this packet.
    • Preclinical studies report heterogeneous, model-specific effects for LR3 IGF-1 and/or native IGF-1 across growth, metabolism, neuropathology markers, and nerve repair, with outcomes varying by analogue, species, age, route, and delivery construct.
    • Mechanistic and structural work supports biological plausibility but does not establish clinical utility. Dosing or safety conclusions for humans are not supported by the packet.

    Evidence by Category

    Human evidence

    • No controlled human clinical trials or direct human-outcome studies for LR3 IGF-1 are included in the packet.
    • The packet does not support dosing or generalized safety conclusions for humans.

    Animal and tissue-engineering studies (preclinical)

    • Growth and gut proliferation (rats; LR3 IGF-1 and/or native IGF-1): Systemic infusion of IGF-1 or LR3 IGF-1 stimulated visceral organ growth and gut tissue proliferation in suckling rats [pubmed:9124573]. These neonatal rat findings are not generalizable to humans.
    • Fetal growth (sheep; native IGF-1 vs LR3 IGF-1):
    • Native IGF-1 infusion increased organ growth in fetal sheep without evidence of increased placental/fetal nutrient transfer [pubmed:33427051]. This prenatal agricultural model has uncertain relevance to adult human outcomes.
    • LR3 IGF-1 did not promote growth in late-gestation growth-restricted fetal sheep [pubmed:39679943]. Model- and condition-specific context limits extrapolation.
    • Islet function (sheep; native IGF-1): A 1-week native IGF-1 infusion in late-gestation fetal sheep reduced glucose-stimulated insulin secretion due to an intrinsic islet defect in that model [pubmed:33938236]; implications beyond this prenatal context are unknown.
    • Neuropathology marker vs function (mice; LR3 IGF-1, intranasal): Intranasal LR3 IGF-1 promoted amyloid plaque remodeling in male 5XFAD mice but did not preserve cognitive function [pubmed:39610283]. Biomarker changes did not translate to behavioral benefit in this model.
    • Peripheral nerve repair (rats; LR3 IGF-1, localized construct): A decellularized Alstroemeria stem-based conduit with GelMA and controlled LR3 IGF-1 release reported enhanced sciatic nerve regeneration in a rat model; effects pertain to this localized tissue-engineering context [pubmed:41015370] and should not be extrapolated to systemic delivery.
    • Protein metabolism (cattle; LR3 IGF-1): LR3 IGF-1 affected protein metabolism in beef heifers [pubmed:10370861]; this agricultural model has uncertain human relevance.
    • Route- and age-dependent intestinal effects (rats; LR3 IGF-1 and/or native IGF-1):
    • LR3 IGF-1 showed preferential intestinal delivery compared with native IGF-1 in preweaning and adult rats [pubmed:12697696]. This rat finding does not establish human oral bioavailability.
    • Systemic, but not orogastric, delivery of IGF-1 or LR3 IGF-1 increased intestinal disaccharidase activity in suckling rats [pubmed:9803447]. Lack of effect via the orogastric route in this model should not be overinterpreted for humans.
    • Reproductive endpoints (rats; LR3 IGF-1): Older reports describe enhanced superovulatory response with LR3 IGF-1 infusion; methodological detail is limited [crossref:10.1016/S0015-0282(97)84896-0; crossref:10.1016/S0015-0282(97)90811-6]. These findings should be viewed as preliminary.

    Applied/analytical and production context

    • Recombinant expression approaches (including Pichia pastoris fusions) and physicochemical characterization of LR3 IGF-1 inclusion bodies are reported [crossref:10.1007/s00253-023-12606-0; crossref:10.1021/bp010058x].
    • Detection of His-tagged LR3 IGF-1 in an unregulated product is described in an analytical report; this is descriptive and nonclinical [crossref:10.1016/j.ghir.2010.07.001].

    Mechanistic and in vitro evidence

    • Structure: Solution NMR characterized the structure and backbone dynamics of LR3 IGF-1 [pubmed:10744677].
    • Signaling modulation (cell system–specific): N-linked glycosylation in Chinese hamster ovary cells was critical for IGF-1 signaling in that system; this study does not distinguish LR3-specific effects [pubmed:36499281].
    • Hematopoietic cell biology: IGF-1 and IGF-binding proteins were involved in proliferation and differentiation of murine bone marrow–derived macrophage precursors in vitro/ex vivo [pubmed:9867252].

    Gaps and limits

    • No direct human efficacy, safety, dose–response, or durability data for LR3 IGF-1 are included in the packet.
    • Findings differ by analogue (native IGF-1 vs LR3 IGF-1), species, age, route, and delivery construct; results from one context do not generalize across models.
    • Rat intestinal-delivery findings should not be taken as evidence of human oral bioavailability [pubmed:12697696; pubmed:9803447].
    • Changes in disease biomarkers without corresponding functional benefit (e.g., amyloid plaque remodeling without cognitive preservation) leave clinical relevance uncertain [pubmed:39610283].
    • Localized tissue-engineering results (e.g., nerve conduit delivery) should not be extrapolated to systemic administration or different indications [pubmed:41015370].
    • The product-detection report is descriptive and does not evaluate safety, efficacy, or manufacturing quality [crossref:10.1016/j.ghir.2010.07.001].

    FAQ

    • Is there human clinical evidence for IGF-1 LR3 in this packet?
    • No. The packet includes no controlled human clinical trials or direct human-outcome studies for LR3 IGF-1.
    • Does IGF-1 LR3 improve cognition in Alzheimer’s-model mice?
    • In male 5XFAD mice, intranasal LR3 IGF-1 remodeled amyloid plaques but did not preserve cognitive function [pubmed:39610283].
    • Do rat intestinal-delivery studies imply oral bioavailability in humans?
    • No. Preferential intestinal delivery and disaccharidase findings are in rats and do not establish human oral bioavailability [pubmed:12697696; pubmed:9803447].
    • Are IGF-1 and LR3 IGF-1 findings interchangeable?
    • No. Effects vary by analogue, species, age, route, and delivery construct; results should not be conflated.
    • What do prenatal or agricultural models (fetal sheep, heifers) tell us about humans?
    • They inform biology in those contexts but have uncertain relevance to adult human outcomes [pubmed:33427051; pubmed:33938236; pubmed:10370861].

    References

    • IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. https://pubmed.ncbi.nlm.nih.gov/39679943/
    • Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. https://pubmed.ncbi.nlm.nih.gov/39610283/
    • Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration. https://pubmed.ncbi.nlm.nih.gov/41015370/
    • Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers. https://pubmed.ncbi.nlm.nih.gov/10370861/
    • IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus. https://pubmed.ncbi.nlm.nih.gov/33427051/
    • Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect. https://pubmed.ncbi.nlm.nih.gov/33938236/
    • Preferential intestinal delivery of long[Arg3] insulin-like growth factor (LR3IGF-I) over IGF-I in preweaning and adult rats. https://pubmed.ncbi.nlm.nih.gov/12697696/
    • Systemically but not orogastrically delivered insulin-like growth factor (IGF)-I and long [Arg3]IGF-I stimulates intestinal disaccharidase activity in two age groups of suckling rats. https://pubmed.ncbi.nlm.nih.gov/9803447/
    • N-Linked Glycosylation in Chinese Hamster Ovary Cells Is Critical for Insulin-like Growth Factor 1 Signaling. https://pubmed.ncbi.nlm.nih.gov/36499281/
    • Involvement of insulin-like growth factor-1 and its binding proteins in proliferation and differentiation of murine bone marrow-derived macrophage precursors. https://pubmed.ncbi.nlm.nih.gov/9867252/
    • Systemic infusion of IGF-I or LR(3)IGF-I stimulates visceral organ growth and proliferation of gut tissues in suckling rats. https://pubmed.ncbi.nlm.nih.gov/9124573/
    • Solution structure and backbone dynamics of long-[Arg(3)]insulin-like growth factor-I. https://pubmed.ncbi.nlm.nih.gov/10744677/
    • In Vivo Infusion With IGF-I Analogue, Long Arg3-Insulin-Like Growth Factor-I (LR3-IGF-I) Enhances Superovulatory Response in Rats. https://doi.org/10.1016/s0015-0282(97)84896-0
    • O-179 In vivo infusion with IGF-I analogue, long Arg3-insulin-like growth factor-I (LR3-IGF-I) enhances superovulatory response in rats. https://doi.org/10.1016/S0015-0282(97)90811-6
    • Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. https://doi.org/10.1007/s00253-023-12606-0
    • Physicochemical Characteristics of LR3-IGF1 Protein Inclusion Bodies: Electrophoretic Mobility Studies. https://doi.org/10.1021/bp010058x
    • Detection of His-tagged Long-R3-IGF-I in a black market product. https://doi.org/10.1016/j.ghir.2010.07.001

    Need current product documentation or small-order review? Small-quantity qualified research purchasers can send a KRL10 order-review request, request current COA availability, review product documentation, or use the catalog-access support path from Kratos Research Labs.

    Launch-week incentive: Use code KRL10 for $10 off eligible RUO catalog orders of $100 or more. Limited to the first 10 coupon uses, one use per customer, through June 4, 2026.

    Research use only. Not for human or veterinary use. Payment instructions are provided after compliance review.

    Send KRL10 review request
    Request documentation
    Start small-order request
    Review single-vial path
    Review small-order shortlist
    Review KRL10 threshold paths
    Quick order review
    Review launch updates
    View product cards
    View price snapshot
    Read ordering FAQ
    Review product docs index
    Review product paths
    Review technical pages
    Review buying checklist
    Review buyer guides